| NCT ID | NCT07452562 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Swansea University |
| Condition | Multiple Sclerosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2026-01-07 |
| Primary Completion | 2027-01-18 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2026-01-07 with a primary completion date of 2027-01-18.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a randomised, double-blind, placebo-controlled trial investigating the effects of Hesperidin supplementation on cognitive function, fatigue, and stress. Participants will be randomly assigned to receive either 500mg of Hesperidin or a matching placebo daily for 12 weeks. The primary outcome is fatigue, with secondary outcomes including cognitive performance and mood. The trial seeks to determine if this dietary intervention offers symptom-alleviating benefits.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Multiple Sclerosis, Aged 18 years or older. Exclusion Criteria: * Known food allergies, intolerances, or significant gastrointestinal (GI) problems, Participants under the age of 18 years.
Contact & Investigator
Hayley A Young, PHD
PRINCIPAL INVESTIGATOR
Swansea University
Frequently Asked Questions
Who can join the NCT07452562 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07452562 currently recruiting?
Yes, NCT07452562 is actively recruiting participants. Contact the research team at h.a.young@swansea.ac.uk for enrollment information.
Where is the NCT07452562 trial being conducted?
This trial is being conducted at Swansea, United Kingdom.
Who is sponsoring the NCT07452562 clinical trial?
NCT07452562 is sponsored by Swansea University. The principal investigator is Hayley A Young, PHD at Swansea University. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.